Guizhou Provincial People's Hospital, Guiyang, China.
Guizhou Medical University, Guiyang, China.
Ann R Coll Surg Engl. 2021 Nov;103(10):752-756. doi: 10.1308/rcsann.2021.0084. Epub 2021 Aug 27.
The aim of the study was to explore the feasibility of performing sentinel lymph node biopsy (SLNB) using a carbon nanoparticle suspension (CNPS) after neoadjuvant chemotherapy in breast cancer patients.
Some 152 patients diagnosed with primary breast cancer (cT1-3N0-2M0) were recruited. Patients were divided into two groups according to axillary lymph node (ALN) status after four to six cycles of neoadjuvant chemotherapy. All patients received a CNPS injection, after which SLNB and axillary lymph node dissection (ALND) were performed.
Sentinel lymph nodes (SLN) of 143 patients were identified; with an accuracy rate of 94.4% and a false-negative rate of 9.9%. Group A included 67 patients, and the detection, accuracy and false-negative rates within this group were 95.5%, 96.9% and 6.7%, respectively. The corresponding rates for group B (85 patients) were 92.9%, 92.4% and 11.8%, respectively.
CNPS is an ideal tracer for improving the detection rate of SLN and can be used to determine SLN status following neoadjuvant chemotherapy.
本研究旨在探讨在乳腺癌患者新辅助化疗后使用碳纳米粒子混悬液（CNPS）进行前哨淋巴结活检（SLNB）的可行性。
共招募了 152 例经诊断患有原发性乳腺癌（cT1-3N0-2M0）的患者。根据新辅助化疗 4-6 个周期后腋窝淋巴结（ALN）的状态，将患者分为两组。所有患者均接受 CNPS 注射，随后进行 SLNB 和腋窝淋巴结清扫术（ALND）。
143 例患者的前哨淋巴结（SLN）被识别，准确率为 94.4%，假阴性率为 9.9%。组 A 包括 67 例患者，该组的检出率、准确率和假阴性率分别为 95.5%、96.9%和 6.7%。组 B（85 例）的相应比率分别为 92.9%、92.4%和 11.8%。
CNPS 是一种理想的示踪剂，可提高 SLN 的检出率，可用于确定新辅助化疗后 SLN 的状态。
